Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
NCT01220115 · View on ClinicalTrials.gov ↗
Study Summary
A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
Conditions Studied
Study Locations (20)
Florida
- Broward Oncology Associates, P.A. — Fort Lauderdale
- Miami Children's Hospital — Miami
- Innovative Medical Research — Miami
- M.D. Anderson Cancer Center Orlando — Orlando
- All Children's Hospital — St. Petersburg
- Central Tampa Hematology and Oncology Associates — Tampa
- St. Joseph Children's Hospital — Tampa
California
- Children's Hospital Oakland (CHO) — Oakland
- Children's Hospital of Orange County Sickle Cell Disease Center — Orange
- Rady Children's Hopsital / UC San Diego University Hospital Sickle Cell Disease Center — San Diego
Illinois
- University of Illinois at Chicago, Dept of Pediatrics — Chicago
- Abington Hematology Oncology Associates, Inc — Oak Lawn
Louisiana
- Tulane University School of Medicine — New Orleans
- LSU Department of Pediatrics Children's Hospital — New Orleans
Maryland
- Johns Hopkins University Division of Hematology — Baltimore
- Oncology-Hematology Associates, P.A. — Clinton
Arkansas
- Hematology Oncology Services of Arkansas — Little Rock
Connecticut
- Hematology Oncology, P.C. — Stamford
District of Columbia
- Howard University — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-09 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220115
The ClinicalTrials.gov registry entry for NCT01220115 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 498 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 60 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT01220115 reports 20 study locations spanning 9 distinct geographic areas — top geographies include Florida, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT01220115 about?
NCT01220115 is a clinical study titled "A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients". A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
What is the current status of trial NCT01220115?
This trial is currently completed. The enrollment target is 498 participants. The study started on 2010-01. Estimated completion is 2014-09.
What conditions does trial NCT01220115 study?
This clinical trial studies the following conditions: Sickle Cell Disease. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT01220115?
This trial is sponsored by Novartis, which has 60 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT01220115 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.